tirzepatide december 19 US judge sides with FDA's removal of Lilly's weight loss drug from shortage list Judge says compounding pharmacies must

GLP-1s are generally considered safe when used as prescribed

Most patients come to us because they feel unheard, rushed, or stuck in a cycle of temporary fixes

Current law blocks Medicare weight-loss drug coverage Policy changes expected mid-2026 Medicaid coverage remains state-dependent What This Means for You Check your specific plan: Self-funded employers can still choose to cover Zepbound During open enrollment: Ask HR about 2026 GLP-1 coverage changes Consider alternatives: Wegovy is covered on most Aetna plans with similar efficacy Self-pay options: TrumpRx ($346/month), LillyDirect ($299-$449/month), or Foundayo (~$149/month oral GLP-1)

Multi-month discounts (injectable semaglutide): 3-month plan at ~$209/mo effective 6-month at ~$191/mo 12-month at ~$174/mo

Evidence supports the role of GLP-1RA as part of therapy in overall ASCVD risk reduction, especially in the cohort with high BMI

Sleep Apnea: These Weight Loss Drugs Can Reduce Sleep Breathing Problems Researchers found tirzepatide significantly reduces the number of breathing interruptions during sleepone of the main factors to measure disease severityfor obese people with moderate-to-severe obstructive sleep apnea